Rapid Tests Market Size & Growth Forecast 2027–2036, By Segments (Product, Technology, Application, End-Use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Rapid Tests Market size was over USD 13.1 billion in 2026 and is likely to grow at a 5.04% CAGR between 2027 and 2036, reaching USD 21.42 billion by 2036. The industry revenue for 2027 is estimated at USD 13.66 billion.
Get more details on this report
Request Free Sample ReportRapid Tests Market Intelligence Snapshot
Regional Market Dynamics
- North America held a 51.82% market share in 2026, supported by advanced diagnostic infrastructure, widespread point-of-care testing, strong purchasing capacity, and routine rapid screening across healthcare settings.
- Asia Pacific is projected to grow at a 9.83% CAGR as healthcare access expands, decentralized diagnostics gain adoption, and demand rises for affordable rapid testing across community care settings.
Segment Momentum
- Consumables held a 66.04% share in 2026 because kits, strips, reagents, and other single-use components require continuous replacement, keeping demand closely tied to testing volumes across healthcare settings.
- Molecular diagnostics is expanding fastest as healthcare providers seek higher analytical precision and more reliable detection, particularly in demanding clinical and near-patient testing environments.
Market Expansion Drivers
- Rising infectious disease burden and aging population driving rapid diagnostic adoption.
- Seasonal respiratory infection surges increasing demand for point-of-care testing solutions.
- Expansion of multiplex home-based self-testing and decentralized diagnostic platforms.
Leading Market Participants
- Major companies in the rapid tests market include Abbott Laboratories (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Becton, Dickinson and Company (United States), Danaher Corporation (United States), Thermo Fisher Scientific Inc. (United States), bioMérieux SA (France), DiaSorin S.p.A. (Italy), Siemens Healthineers AG (Germany), QuidelOrtho Corporation (United States), Sysmex Corporation (Japan).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 13.1 billion
- 2027 Estimated Market Size: USD 13.66 billion.
- Projected Market Size: USD 21.42 billion by 2036
- Growth Forecast: 5.04% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Consumables (Product) | Immunoassay (Technology) | Upper Respiratory Tract Infections (Application) | Hospitals & Clinics (End-Use)
- Emerging Opportunity Segment: Instruments (Product) | Molecular Diagnostics (Technology) | Antibiotic Resistant Infections (Application) | At-home Testing (End-Use)
Market Growth Drivers and Industry Trends
Rising infectious disease burden and aging population driving rapid diagnostic adoption
A higher infectious disease burden combined with an aging population is increasing the need for timely and accessible diagnostic solutions. Rapid tests market growth is supported by the ability of rapid diagnostics to provide convenient testing and quicker clinical decision support, particularly where efficient identification of health conditions is important for patient management.
Seasonal respiratory infection surges increasing demand for point-of-care testing solutions
Seasonal increases in respiratory infections create recurring demand for diagnostic tools that can be used close to the patient and provide timely results. The rapid tests market gains from this requirement as healthcare providers and other testing settings use point-of-care solutions to support prompt identification of respiratory infections and facilitate appropriate care decisions.
Expansion of multiplex home-based self-testing and decentralized diagnostic platforms
The expansion of multiplex self-testing and decentralized diagnostic platforms is moving diagnostic activity closer to consumers and community-based settings. Rapid tests market adoption is strengthened as home-based and decentralized solutions offer greater testing convenience while multiplex formats allow users to assess multiple conditions through a more streamlined testing experience.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Increased demand for rapid diagnostic testing | 3.00% | Short term (≤ 2 yrs) | North America, Europe | Medium | Fast |
| Expansion of healthcare infrastructure | 2.50% | Medium term (2–5 yrs) | Asia Pacific, Latin America | Low | Moderate |
| Rising prevalence of infectious diseases | 3.20% | Long term (5+ yrs) | Global | Low | Slow |
| Rising infectious disease burden and aging population driving rapid diagnostic adoption | 2.60% | High | North America, Asia Pacific | High | Near Term |
| Seasonal respiratory infection surges increasing demand for point-of-care testing solutions | 2.20% | High | North America, Europe | High | Near Term |
| Expansion of multiplex home-based self-testing and decentralized diagnostic platforms | 1.90% | High | Asia Pacific, Latin America | Emerging | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America dominated the rapid tests market with a 51.82% share in 2026, reflecting extensive healthcare infrastructure, strong diagnostic awareness, and widespread use of point-of-care testing across clinical and community settings. Demand for rapid diagnostic solutions is supported by the need for timely disease identification, decentralized healthcare delivery, and convenient testing outside conventional laboratory environments. Established regulatory and healthcare systems facilitate the adoption of validated diagnostic technologies, while increasing emphasis on early detection and infection management supports continued utilization. Technological advances that improve test accuracy, portability, and ease of use are also strengthening the region's established market position.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is the fastest-growing region as healthcare access expands and demand for affordable, convenient diagnostic solutions increases. Growing investment in healthcare infrastructure, particularly across developing economies, is improving access to point-of-care testing in hospitals, clinics, pharmacies, and community settings. Rising awareness of infectious diseases and preventive healthcare is encouraging broader use of rapid diagnostics, while improvements in local healthcare delivery are making decentralized testing more practical. The need for efficient screening and faster clinical decision-making is further supporting adoption as healthcare systems seek diagnostic approaches that can operate effectively beyond centralized laboratories.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Quality Validation HubGermany prioritizes clinically validated rapid tests that align with stringent regulatory expectations and healthcare quality standards. Demand in Germany remains centered on reliable point-of-care diagnostics for hospitals, outpatient clinics, and occupational health applications.
France 🇫🇷
Public Health ReadinessFrance continues strengthening rapid testing capabilities within community healthcare and preventive screening initiatives. Healthcare providers across France focus on dependable diagnostic solutions that enable timely clinical decisions while supporting broader disease monitoring programs.
Italy 🇮🇹
Community Care SupportItaly prioritizes rapid diagnostic solutions that improve accessibility across hospitals, pharmacies, and regional healthcare networks. The Italian market increasingly values cost-effective, easy-to-use rapid tests that streamline patient triage and routine infectious disease detection.
Japan 🇯🇵
Precision Diagnostics FocusJapan advances rapid test adoption through highly accurate diagnostic solutions suited for aging populations and routine clinical workflows. Japanese healthcare providers increasingly favor compact, user-friendly testing systems that support efficient patient management.
South Korea 🇰🇷
Digital Testing IntegrationSouth Korea combines rapid testing technologies with digital healthcare platforms to improve accessibility and reporting efficiency. Domestic developers in South Korea actively introduce innovative diagnostic kits for infectious diseases while expanding export-ready product portfolios.
United States 🇺🇸
Innovation CommercializationThe U.S. rapid tests market emphasizes expanding decentralized diagnostics across pharmacies, workplaces, and home settings. Manufacturers in the U.S. continue investing in multiplex testing platforms and digital result integration to strengthen infectious disease surveillance and routine screening.
Segment Leadership and Growth Trends
Rapid Tests Market Share (%), by Product, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportProduct Segment Analysis: Consumables (Largest Segment) vs Instruments (Fastest-Growing Segment)
In the rapid tests market, consumables represented the largest segment in 2026 with a 66.04% share, reflecting their essential role in the recurring use of rapid diagnostic procedures. Test kits, reagents, cartridges, and related disposable components are continuously required across healthcare, screening, and diagnostic settings, creating dependable demand as testing volumes expand. Their convenience, ease of deployment, and suitability for decentralized testing also support widespread utilization where rapid results are needed to guide timely clinical or operational decisions.
Instruments are gaining momentum as rapid testing increasingly incorporates more sophisticated analytical and automated capabilities. Instrument-based platforms can improve workflow consistency, support multiplex testing, and enhance the processing of diagnostic samples in settings that require greater throughput or analytical precision. The broader shift toward decentralized diagnostics and technology-enabled testing is encouraging investment in compact, user-friendly instruments that can complement rapid testing workflows across diverse healthcare environments.
Technology Segment Analysis: Immunoassay (Largest Segment) vs Molecular Diagnostics (Fastest-Growing Segment)
Immunoassay technology held the largest share of the rapid tests market in 2026 at 55.07%, supported by its established use in detecting a broad range of biomarkers, pathogens, and disease-related targets. The technology offers practical advantages in terms of accessibility, workflow simplicity, and suitability for rapid screening applications. Its established presence across clinical and point-of-care environments, combined with continued demand for convenient diagnostic testing, reinforces immunoassay as a major technology platform within rapid testing.
Molecular diagnostics are advancing rapidly as healthcare providers place greater emphasis on highly specific pathogen and genetic target detection. Molecular approaches can provide sensitive identification of infectious agents and support more informed diagnostic decisions, particularly where rapid differentiation between conditions is important. Improvements in assay design, miniaturization, automation, and point-of-care molecular platforms are broadening their usability and supporting greater integration of molecular technologies into rapid diagnostic workflows.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Product | Instruments, Consumables, Others | Consumables | Instruments |
| Technology | Immunoassay, Molecular Diagnostics, Others | Immunoassay | Molecular Diagnostics |
| Application | Upper Respiratory Tract Infections, Antibiotic Resistant Infections, Sepsis | Upper Respiratory Tract Infections | Antibiotic Resistant Infections |
| End-Use | Hospitals & Clinics, Laboratories, At-home Testing, Others | Hospitals & Clinics | At-home Testing |
Competitive Landscape and Market Positioning
Top players in the rapid tests market:
1. Abbott Laboratories (United States)
2. F. Hoffmann-La Roche Ltd. (Switzerland)
3. Becton Dickinson and Company (United States)
4. Danaher Corporation (United States)
5. Thermo Fisher Scientific Inc. (United States)
6. bioMérieux SA (France)
7. DiaSorin S.p.A. (Italy)
8. Siemens Healthineers AG (Germany)
9. QuidelOrtho Corporation (United States)
10. Sysmex Corporation (Japan)
The rapid tests market is growing due to increasing need for quick diagnostic decision-making in healthcare settings. Advancements in assay sensitivity are improving accuracy and reliability. The rapid tests market is also witnessing expansion of point-of-care testing solutions. Innovation focuses on reducing turnaround time while maintaining diagnostic precision.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories (United States) | |||||||
| F. Hoffmann-La Roche Ltd. (Switzerland) | |||||||
| Becton Dickinson and Company (United States) | |||||||
| Danaher Corporation (United States) | |||||||
| Thermo Fisher Scientific Inc. (United States) | |||||||
| bioMérieux SA (France) | |||||||
| DiaSorin S.p.A. (Italy) | |||||||
| Siemens Healthineers AG (Germany) | |||||||
| QuidelOrtho Corporation (United States) | |||||||
| Sysmex Corporation (Japan). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| MedGenome | Feb-26 | MedGenome launched MetaSeq, a metagenomic next-generation sequencing (mNGS) assay capable of identifying over 1,400 pathogens directly from blood samples. By utilizing microbial cell-free DNA to bypass traditional culture methods, the technology provides a faster diagnostic alternative for bloodstream infections, offering a significant improvement in sensitivity and turnaround time compared to conventional testing. |
| Fiocruz | Dec-25 | Fiocruz and bioMérieux formalized a strategic partnership to establish a joint Research, Development, and Innovation Center for diagnostics in Rio de Janeiro. The initiative, slated for operation in March 2026, integrates local production facilities to accelerate the development of diagnostic technologies and strengthen manufacturing capacity for rapid diagnostic solutions in the region. |
| Nanopath | Nov-25 | The FDA granted Breakthrough Device designation to Nanopath’s molecular diagnostic platform for detecting complicated urinary tract infections (cUTIs). This regulatory milestone provides the company with prioritized review pathways and accelerated feedback, reflecting the strategic importance of developing rapid, culture-free diagnostic solutions that can significantly reduce time-to-result in clinical practice. |
| Avitia | Oct-25 | Avitia entered a partnership with Genoscience to deploy advanced rapid cancer testing services across a network of over 50 private clinics in Québec. This collaboration significantly expands regional diagnostic reach and improves patient accessibility, demonstrating an integrated clinical model for scaling the commercialization of rapid cancer detection solutions within the primary care ecosystem. |
| Triverity | Aug-25 | Triverity received FDA clearance for its Exact Dx sepsis assay, designed for use in acute care and point-of-care settings. The test enables rapid detection of sepsis-associated biomarkers, facilitating earlier clinical intervention and improved risk stratification for patients, thereby enhancing operational capabilities for rapid diagnostics in emergency healthcare environments. |
| Codix Bio | May-25 | Codix Bio secured a license to manufacture a new generation of rapid diagnostic tests through a WHO and Medicines Patent Pool–brokered agreement. This royalty-free arrangement facilitates the local production of advanced diagnostic technologies in Nigeria, effectively expanding manufacturing access and supply chain resilience for essential diagnostic tools in emerging markets. |
| Onda | Apr-25 | Onda secured funding to develop a rapid disease testing solution specifically for the aquaculture industry. The project aims to enhance biosecurity and operational efficiency by enabling faster, cost-effective detection of pathogens in fish and shellfish, marking a strategic diversification of rapid diagnostic technology into high-growth agricultural and food-security applications. |
| Inflammatix | Jan-25 | The FDA granted 510(k) clearance to the Inflammatix TriVerity molecular test, which analyzes immune-related gene expression to differentiate between bacterial and viral infections. This diagnostic innovation provides clinicians with a rapid risk score for sepsis, representing a shift toward advanced host-response diagnostics for more precise patient management and antimicrobial stewardship. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Rapid Tests Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Sample Type | Blood, Urine, Saliva, Nasal & Respiratory Samples, Stool, Other Clinical Samples |
| Testing Purpose | Screening, Diagnosis, Monitoring, Treatment Guidance |
| Purchase Channel | Direct Institutional Procurement, Distributors & Wholesalers, Retail Pharmacies, E-commerce |
Rapid Tests Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Point-of-Care Testing Adoption and Healthcare Access |
|
| Regulatory Pathways and Market Access Strategy |
|
| Healthcare Procurement and Emerging Disease Preparedness |
|
Need a different cut of the data?
Request Custom ResearchWhat is the market valuation of rapid tests?
How is the rapid tests industry size expected to evolve during the forecast period?
How is the shift toward decentralized and home-based testing models impacting demand in the rapid tests market?
What is driving the growing preference for molecular diagnostics within rapid testing technologies?
Why do consumables lead the rapid tests market?
Why is molecular diagnostics the fastest-growing technology in the rapid tests market?
Why does North America dominate the rapid tests market?
What is driving rapid tests market growth in Asia Pacific?
Which companies dominate the rapid tests landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization